Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens

Author(s): Hiroaki Uchida*, Hirofumi Hamada, Kenji Nakano, Heechung Kwon, Hideaki Tahara, Justus B. Cohen, Joseph C. Glorioso

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 2 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the identification of mutations that favor its replication in tumor over normal cells. However, these attenuating mutations also tend to limit the potency of current oncolytic HSV vectors that have entered clinical studies. As an alternative, vector retargeting to novel entry receptors has the potential to achieve tumor specificity at the stage of virus entry, eliminating the need for replication-attenuating mutations. Here, we summarize the molecular mechanism of HSV entry and recent advances in the development of fully retargeted HSV vectors for oncolytic virotherapy. Retargeted HSV vectors offer an attractive platform for the creation of a new generation of oncolytic HSV with improved efficacy and specificity.

Keywords: Cancer, gene therapy, herpes simplex virus, oncolytic virus, targeting, vector, virotherapy, virus entry.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 05 February, 2017
Page: [162 - 170]
Pages: 9
DOI: 10.2174/1568009617666170206105855
Price: $65

Article Metrics

PDF: 45
HTML: 10